Oh yes, Charter was part of AMDL Australia, licensed to distribute AMDL's DR-70 kits since 2003 I believe (forgive me if I don't look up the exact year).
All clinical trials using DR-70 were done by researchers who simply got DR-70 from Radient or another supplier. The researchers didn't have the IP -- they didn't manufacture DR-70, they just bought the kits. One kit costs about $295 - $400 (I find conflicting prices on the internet) and each kit produces 96 tests.
The "Mayo Study" used 1000 tests. Charter claims to have conducted 6,600 tests. That is 68.75 kits which would have cost him somewhere around $25,000, maybe less when buying from AMDL in 2002 - 2008.
But I don't think Charter tested 6,600 individuals and that's one of the reasons we don't see the results published. I think that 6,600 participants is a crazy claim. If the test worked, there's no need to test that many people.
Saliva contains fibrin degradation products. Charter's "invention" was to try using DR-70 on saliva instead of blood. That's not what I would call an "invention" - that is an "idea," like using WD-40 on crankbaits to get fish to bite.
I use the WD-40 metaphor because that's what I think Charter and Gartner are doing. I think they are fishing for investors.
